History

Cerebrolysin is manufactured by EVER Neuro Pharma of Unterach, Austria, formerly EBEWE Pharma, which owned the product until 2008. It carries the development code FPF-1070. Widely repeated accounts of a late-1940s origin, a named inventor, a 1954 Austrian approval and a later switch from acid to enzymatic processing trace only to peptide-vendor and wiki blogs that disagree with one another, so they cannot be treated as established. What is verifiable is the modern trial record: the neutral CASTA stroke trial in 2012, the sponsor-funded CARS trial in 2016, and Cochrane reviews of vascular dementia and acute ischemic stroke updated in 2019 and 2023.

Cerebrolysin is one of the more genuinely studied compounds in the “nootropic peptide” category. Unlike most research peptides, it has a real prescription history abroad, multiple randomized controlled trials, and several Cochrane systematic reviews. That sounds promising until you look at what those trials actually found. The largest, most rigorous test of its flagship use came up neutral, and the most independent syntheses of the evidence describe modest or uncertain effects at best. This profile walks through what Cerebrolysin is, what it is claimed to do, and what the strongest evidence actually shows.

What it is

Cerebrolysin is not a single molecule. It is a complex preparation made by standardized enzymatic breakdown of purified pig (porcine) brain protein using pancreatic enzymes. The marketed concentrate is commonly cited at 215.2 mg/mL of peptide and amino-acid material. Secondary and manufacturer literature describes it as roughly three-quarters free amino acids and one-quarter low-molecular-weight peptides, with peptide sizes below about 10,000 daltons. That split is an approximate figure from review and manufacturer sources, not a precisely audited specification. Because it is a peptide and amino-acid mixture, it is given by injection or IV infusion; taken orally it would simply be digested.

The proposed mechanism is that the peptide fraction mimics the body’s own neurotrophic factors, such as BDNF, GDNF, NGF and CNTF, and switches on downstream signaling tied to neuroprotection and brain plasticity. There are real reasons for caution here. Reference summaries note that the specific molecular effects “are not clear,” and that the half-life of BDNF in the bloodstream is only about ten minutes, which raises questions about how an injected mixture would sustain trophic signaling. More fundamentally, Cerebrolysin has no single defined active ingredient. Its composition is known to vary by batch and manufacturer, and the active components are not fully characterized. That lack of a defined active pharmaceutical ingredient is one core reason it does not fit the regulatory framework used in the United States.

The claims

The manufacturer’s registered indications are cerebrovascular disorders: dementia of the Alzheimer’s type, vascular dementia, stroke, and craniocerebral trauma. Beyond these, it has been studied for traumatic brain injury recovery, post-stroke motor and language rehabilitation, and cognition in schizophrenia.

On the gray market it is marketed far more aggressively, as a general “nootropic,” a cognitive enhancer, a neuroprotectant, and a tool for “brain repair” or brain anti-aging in otherwise healthy people. These last claims are not supported by sound evidence. The independent Alzheimer’s Drug Discovery Foundation assessment is blunt on this point: there are zero clinical studies on dementia prevention or on cognition in healthy adults.

The evidence

Stroke is the strongest test of Cerebrolysin, and the result is essentially negative. The CASTA trial (Heiss et al., 2012) was the largest randomized controlled trial, enrolling 1,070 patients with acute ischemic stroke at mostly Chinese centers. Its primary endpoint, a combined measure of disability and neurological function at day 90, was not statistically significant. A post-hoc analysis suggested lower mortality in the Cerebrolysin arm and a possible benefit in more severely affected patients, but post-hoc subgroups are hypothesis-generating only and cannot rescue a neutral primary endpoint.

The 2023 Cochrane review of Cerebrolysin for acute ischemic stroke pooled seven trials and 1,773 participants. On moderate-certainty evidence it found no effect on death from any cause. It also found that non-fatal serious adverse events may be increased, with a relative risk of 2.39 (95% CI 1.10 to 5.23) on moderate-certainty evidence. That is a meaningful counterpoint to the “well-tolerated” framing the product usually receives.

A more positive stroke signal comes from the CARS trial (Muresanu et al., 2016), which found a benefit on arm motor recovery after stroke. But CARS was small (about 205 patients analyzed), was funded by EVER Neuro Pharma, and had multiple authors with financial ties to the manufacturer.

Vascular dementia. The 2019 Cochrane review covered six studies and 597 participants and did report beneficial effects on cognition, responder rates and global function. However, all of this rested on very-low-quality evidence affected by imprecision, indirectness and serious risk of bias, and the reviewers described the effect as modest and possibly not important to people actually living with dementia.

Alzheimer’s disease. Several small trials have shown modest signals on standard cognitive scales. The ADDF summary of the field (three meta-analyses and six RCTs) characterizes the effect in mild-to-moderate Alzheimer’s as modest, smaller than approved Alzheimer’s drugs, mostly from small or unconfirmed studies, and with no prevention data at all.

Traumatic brain injury. A 2018 meta-analysis (Ghaffarpasand et al.) pooled five studies and 5,685 participants and found favorable pooled effects on outcome scales. The major caveat is that four of those five studies were non-randomized cohort designs, and the authors themselves rated the evidence only at “Level II,” acknowledging the absence of high-quality randomized trials.

Stepping back, the pattern is consistent. There is no large, independent, confirmatory trial with a met primary endpoint for any indication. The one large, rigorous stroke trial was neutral. The positive signals lean heavily on manufacturer funding, post-hoc subgroups, surrogate or rehabilitation scales, non-randomized data, and evidence the reviewers themselves rate as low or very-low certainty. For context, independent science-watchdog reporting has also scrutinized parts of Cerebrolysin’s preclinical literature and some authors linked to the manufacturer; that reporting is editorial and not peer-reviewed, so it is background rather than fact, but it is part of why the evidence base draws skepticism. This is why the grade here is “Preliminary human,” at the lower end of that band: there is far more human data than a typical research peptide, but it does not confirm the marketed benefits.

Safety and side effects

In trials and post-marketing use, reported side effects are generally mild and transient: dizziness or vertigo, a sensation of heat, sweating, headache and nausea. Agitation, insomnia and confusion have been linked to a stimulatory effect, and injecting it too quickly can cause palpitations. Prescribing information lists contraindications including epilepsy, kidney disease and hypersensitivity; manufacturer prescribing documents phrase this more narrowly as status epilepticus, grand mal epilepsy and severe renal impairment.

Two cautions deserve weight. First, the 2023 Cochrane review’s finding of a possible increase in non-fatal serious adverse events complicates the usual “safe and well-tolerated” message. Second, long-term safety and the specific risks of a porcine, brain-derived, injected product, such as immunogenicity and theoretical transmissible-agent concerns, are not well characterized in independent literature. On the gray market, where vials are sold as “research chemicals” with no oversight, contamination, sterility and counterfeiting are real and additional concerns.

Legal and regulatory status

Cerebrolysin is not approved by the FDA and is not legal to sell or market in the United States. Its presence in the FDA’s substance registry carries an explicit note that this does not imply any regulatory review or approval. The ADDF likewise confirms it is not approved in the US for any condition. Claims that it holds an FDA orphan-drug designation appear to be unfounded; a search turns up none, and the relevant orphan designations belong to entirely different drugs.

Abroad, it is a prescription medicine in Austria, Russia, China and South Korea, and is reportedly registered in 50 or more mostly Eastern European, Asian and Latin American countries, though that count comes from secondary and manufacturer sources rather than an independent audit.

On anti-doping, Cerebrolysin is not named on the WADA Prohibited List. The growth-factor category (numbered S2.3 in the 2026 list) prohibits growth factors and modulators affecting muscle, tendon or ligament protein synthesis or degradation, vascularization, energy utilization, regenerative capacity or fiber-type switching, with named examples including IGF-1, FGFs, HGF, MGFs, PDGF, VEGF and Thymosin-β4. Nerve growth factor and neurotrophic factors are not listed, and the catch-all targets musculoskeletal and performance effects rather than neural ones, so Cerebrolysin is not clearly captured. That said, the list uses “including but not limited to” language, and contamination of gray-market products is possible, so athletes should be cautious.

Bottom line

Cerebrolysin is the rare research peptide with a genuine clinical literature behind it, and that is exactly why it is instructive. When you set aside the manufacturer-funded studies, post-hoc subgroups and non-randomized cohorts, what remains is underwhelming: the largest rigorous stroke trial was neutral, the most independent dementia evidence is very-low-certainty and modest, and the highest-quality stroke review found no mortality benefit alongside a possible increase in serious adverse events. There is no credible support for using it as a cognitive enhancer in healthy people. For anyone weighing it, the honest summary is that decades of study have not produced a convincing, independently replicated benefit for its headline uses, and that its undefined composition and unregulated gray-market supply add real uncertainty on top of that.

Cerebrolysin: A Heavily Studied Brain Peptide Whose Best Trials Came Up Short